New oral drug for chronic hives
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have had chronic spontaneous urticaria (hives that last more than 6 weeks) for at least 6 months
- You have been on a stable dose of a second-generation antihistamine (like cetirizine, loratadine, or fexofenadine) for at least 2 weeks and are willing to keep taking it
- Your hives are not caused by a specific trigger (like pressure, cold, heat, or sweating)
- You do not have another chronic itchy skin condition (like eczema or psoriasis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This study tests a new oral medication (TLL-018) for people with chronic hives that don't fully go away with standard antihistamines. It aims to see if the drug reduces itching and hives better than placebo.
This trial tests a new daily pill called TLL-018 (a JAK inhibitor) for people with chronic hives that still cause symptoms despite taking antihistamines. It aims to see how fast it relieves itching and hives.
This study tests an investigational pill called THB335 for adults whose hives (itchy welts) keep appearing despite taking antihistamines. The goal is to see if this treatment can reduce itching and hives and improve quality of life.
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
This study tests a new medication called MG-K10 for people with chronic hives (itchy welts) that don't go away with standard antihistamines. It aims to see if the drug can reduce itching and hives, possibly offering another treatment option.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.